| Patent application number | Description | Published |
|---|
| 20080200659 | Combinatorial polyketide libraries produced using a modular PKS gene cluster as scaffold - Combinatorial libraries of polyketides can be obtained by suitable manipulation of a host modular polyketide synthase gene cluster such as that which encodes the PKS for erythromycin. The combinatorial library is useful as a source of pharmaceutically active compounds. In addition, novel polyketides and antibiotics are prepared using this method. | 08-21-2008 |
| 20080213245 | ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE - Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 09-04-2008 |
| 20080213427 | ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE - Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 09-04-2008 |
| 20080213822 | METHODS FOR DIAGNOSING CELIAC SPRUE AND REAGENTS USEFUL THEREIN - Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 09-04-2008 |
| 20080233102 | Drug Therapy for Celiac Sprue - Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 09-25-2008 |
| 20080299108 | Peptides for Diagnostic and Therapeutic Methods for Celiac Sprue - Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses. | 12-04-2008 |
| 20090042806 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF - Transglutaminase inhibitors and methods of use thereof are provided. | 02-12-2009 |
| 20090111151 | Production of Polyketides - Recombinant host cells of the suborder Cystobacterineae containing recombinant expression vectors that encode heterologous PKS genes can produce polyketides synthesized by the PKS enzymes encoded on those vectors at high levels. | 04-30-2009 |
| 20090156490 | PEPTIDES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR CELIAC SPRUE - Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses. | 06-18-2009 |
| 20090170172 | Recombinant Methods and Materials for Producing Epothilone and Epothilone Derivatives - Recombinant nucleic acids that encode all or a portion of the epothilone polyketide synthase (PKS) are used to express recombinant PKS genes in host cells for the production of epothilones, epothilone derivatives, and polyketides that are useful as cancer chemotherapeutics, fungicides, and immunosuppressants. | 07-02-2009 |
| 20090186378 | Polynucleotides encoding the fkbB gene of the FK-520 polyketide synthase gene cluster - Host cells comprising recombinant vectors encoding the FK-520 polyketide synthase and FK-520 modification enzymes can be used to produce the FK-520 polyketide. Recombinant DNA constructs comprising one or more FK-520 polyketide synthase domains, modules, open reading frames, and variants thereof can be used to produce recombinant polyketide synthases and a variety of different polyketides with application as pharmaceutical and veterinary products. | 07-23-2009 |
| 20090280555 | ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE - Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 11-12-2009 |
| 20090312260 | DRUG THERAPY FOR CELIAC SPRUE - Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 12-17-2009 |
| 20090312272 | Transglutaminase inhibitors and methods of use thereof - Transglutaminase inhibitors and methods of use thereof are provided. | 12-17-2009 |
| 20100092451 | Combination Enzyme Therapy for Digestion of Dietary Gluten - A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy. | 04-15-2010 |
| 20100196955 | Scaleable Manufacturing Process for Cysteine Endoprotease B, Isoform 2 - Methods are provided for the production of gram to kilogram quantities of pro-EP-B2 (proenzyme form of EP-B2) in a lyophilized form. The methods include scalable fermentation, refolding and purification processes, which processes may be combined with lyophilization to yield a stable product. | 08-05-2010 |
| 20100317025 | Diagnostic Method for Celiac Sprue - Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. | 12-16-2010 |
| 20100322912 | Combination Enzyme Therapy for Gastric Digestion of Dietary Gluten in Celiac Sprue Patients - Combination enzyme products and methods of use thereof are provided. Aspergillopepsin I is combined with a protease enzyme that provides for an additive or synergistic effect in the digestion of toxic gluten oligopeptides. The enzyme products are useful in the treatment of Celiac Sprue patients, particularly for patients who continue to exhibit signs or symptoms of active disease despite following a gluten-free diet. | 12-23-2010 |
| 20110027897 | Biomarker to Measure Drug Efficacy in Enteropathic Disease - The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label. | 02-03-2011 |
